The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease
Open accessAbstract
The neurodegenerative disease Huntington’s Disease (HD) is caused by an expanded polyglutamine (polyQ) tract in the protein huntingtin (htt). Although the gene encoding htt was identified and cloned more than 15 years ago, and in spite of impressive efforts to unravel the mechanism(s) by which mutant htt induces nerve cell death, these studies have so far not led to a good understanding of pathophysiology or an effective therapy. Set against a historical background, we review data supporting the idea that metabolites of the kynurenine pathway (KP) of tryptophan degradation provide a critical link between mutant htt and the pathophysiology of HD. New studies in HD brain and genetic model organisms suggest that the disease may in fact be causally related to early abnormalities in KP metabolism, favoring the formation of two neurotoxic metabolites, 3-hydroxykynurenine and quinolinic acid, over the related neuroprotective agent kynurenic acid. These findings not only link the excitotoxic hypothesis of HD pathology to an impairment of the KP but also define new drug targets and therefore have direct therapeutic implications. Thus, pharmacological normalization of the imbalance in brain KP metabolism may provide clinical benefits, which could be especially effective in the early stages of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278 · cited 1×
“Moreover, endogenous agents such as steroid hormones and cytokines were found to stimulate the activity of individual KP enzymes and may therefore have distinct effects on the function of neuroactive KP metabolites (Andre et al., 2008; Heyes et al., 1997; O’Connor et al., 2008; Oxenkrug, 2007).”
Background2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia
Sheardown, M. J., Nielsen, E. Ø., Hansen, A. J., Jacobsen, P., & Honoré, T. (1990) · Science · doi:10.1126/science.2154034 · Cited by 1,138
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 1×
“…reader is referred to authoritative summaries and reviews of the subject (Aarts and Tymianski, 2004; Beal, 1992; Besancon et al., 2008; Bossy-Wetzel et al., 2004; Fagni et al., 1994; Greene and Greenamyre, 1996; Johnston, 2005; Leist et al., 1997; Mattson, 2007; Nicotera and Lipton, 1999).”
BackgroundQuinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 1×
“…reporting NMDA receptor-mediated excitation following the ionophoretic application of the tryptophan metabolite quinolinic acid (pyridine-2,3-dicarboxylic acid; QUIN) to rat cortical neurons (Stone and Perkins, 1981) attracted our attention during our own search for novel endogenous excitotoxins.”
BackgroundMolecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Monitoring tryptophan metabolism in chronic immune activation
Schröcksnadel, K., Wirleitner, B., Winkler, C., & Fuchs, D. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.013 · Cited by 551 · cited 2×
“…is currently primarily concerned with indoleamine-2,3-dioxygenase (IDO), one of the two enzymes responsible for the initial oxidative opening of tryptophan’s indole ring (the other one being the more substratespecific tryptophan-2,3-dioxygenase) (Schröcksnadel et al., 2006; Xu et al., 2008).”
BackgroundTryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519 · cited 1×
“…both 3-HK and KYNA have until now received more attention for their possible involvement in neurological and psychiatric diseases (Moroni, 1999; Müller and Schwarz, 2007; Németh et al., 2006; Oxenkrug, 2007; Ruddick et al., 2006; Schwarcz and Pellicciari, 2002; Stone and Darlington, 2002).”
BackgroundMicroglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440 · cited 1×
“Most interestingly, microglial activation in these preclinical HD cases correlated inversely with striatal neuronal dysfunction, as determined by loss of dopamine receptor binding (Tai et al., 2007).”
BackgroundAcute dendrotoxic changes in the hippocampus of kainate treated rats
Olney, J. W., Fuller, T., & De Gubareff, T. (1979) · Brain Research · doi:10.1016/0006-8993(79)90872-2 · Cited by 300
Caldeira, M. V., Melo, C. V., Pereira, D. B., Carvalho, R., Correia, S. S., Backos, D. S., Carvalho, A. L., Esteban, J. A., & Duarte, C. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700607200 · Cited by 251
Differential vulnerability of central neurons of the rat to quinolinic acid
Schwarcz, R., & Köhler, C. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90115-5 · Cited by 239
Self-citationRole of Kynurenines in the Central and Peripherial Nervous Systems
Nemeth, H., Toldi, J., & Vecsei, L. (2005) · Current Neurovascular Research · doi:10.2174/1567202054368326 · Cited by 169 · cited 1×
“Almost without exception, the usefulness of the new synthetic compounds for the study of brain KP metabolism in vivo is restricted by their difficulty to cross the blood–brain barrier after systemic administration (cf. Németh et al., 2005).”
Background
Cited by
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Self-citationLovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Metadata
- Authors
- Schwarcz, R., Guidetti, P., Sathyasaikumar, K. V., & Muchowski, P. J.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 90
- Issue
- 2
- Pages
- 230-245
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W1982792716
- Cited by
- 176
- References
- 15
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.